Orchestra BioMed Holdings, Inc. (OBIO) Cash Flow Statement
Orchestra BioMed Holdings, Inc. (OBIO) generated -$58.3M of operating cash flow over the twelve months to 2026-06-30, spent $781000 on capital expenditure and had free cash flow of -$59.1M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
OBIOOrchestra BioMed Holdings, Inc.Follow OBIO — free
—
Price chart with a free account
- Market cap
- 336.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 16 Nov, in 23 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -46.1 | -50.6 | -49.0 | -58.3 | |
| Capital expenditure | 0.1 | 0.3 | 0.5 | -0.8 | |
| Free cash flow | -46.2 | -50.8 | -49.5 | -59.1 | |
| Stock-based compensation | 7.6 | 10.6 | 12.0 | — |
USD millions · SEC XBRL
Orchestra BioMed Holdings, Inc. — questions
- What is Orchestra BioMed Holdings, Inc.'s operating cash flow?
- -$58.3M over the twelve months to 2026-06-30.
- How much does Orchestra BioMed Holdings, Inc. spend on capital expenditure?
- $781000 over the twelve months to 2026-06-30.
- What is Orchestra BioMed Holdings, Inc.'s free cash flow?
- -$59.1M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Orchestra BioMed Holdings, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.